id,conversation_id,created_at,date,time,timezone,user_id,username,name,place,tweet,language,mentions,urls,photos,replies_count,retweets_count,likes_count,hashtags,cashtags,link,retweet,quote_url,video,thumbnail,near,geo,source,user_rt_id,user_rt,retweet_id,reply_to,retweet_date,translate,trans_src,trans_dest
1384840669752090625,1384840667747258371,2021-04-21 17:35:19 IST,2021-04-21,17:35:19,+0530,3213634851,fortressbio,Fortress Biotech,,"A webcast of the company’s fireside chat will be available on the Events page of the Investor Relations section of Mustang’s website,  https://t.co/MoRh4WbG2l, for approximately 30 days after the meeting. $MBIO $FBIO",en,[],['http://www.mustangbio.com'],[],1,1,0,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1384840669752090625,False,,0,,,,,,,,[],,,,
1384840668783259648,1384840667747258371,2021-04-21 17:35:19 IST,2021-04-21,17:35:19,+0530,3213634851,fortressbio,Fortress Biotech,,".@Mustang_Bio will participate in a fireside chat on Monday, April 26, 2021, at 3:15 p.m. ET and will also participate in one-on-one meetings during the conference.  https://t.co/RCRsbqzbaW $MBIO $FBIO",en,"[{'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/347/mustang-bio-to-participate-in-chardans-5th-annual'],[],1,0,0,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1384840668783259648,False,,0,,,,,,,,[],,,,
1384840667747258371,1384840667747258371,2021-04-21 17:35:18 IST,2021-04-21,17:35:18,+0530,3213634851,fortressbio,Fortress Biotech,,".@Mustang_Bio announced that Manuel Litchman, M.D., President and Chief Executive Officer, and Knut Niss, Ph.D., Chief Technology Officer, will participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit.  https://t.co/RCRsbqzbaW $MBIO $FBIO",en,"[{'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/347/mustang-bio-to-participate-in-chardans-5th-annual'],[],2,0,0,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1384840667747258371,False,,0,,,,,,,,[],,,,
1381922684288765954,1381922684288765954,2021-04-13 16:20:17 IST,2021-04-13,16:20:17,+0530,3213634851,fortressbio,Fortress Biotech,,Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol  https://t.co/ObuAbblM8t $ATXI $FBIO,en,[],['https://bit.ly/3uMYunH'],[],3,4,13,[],"['atxi', 'fbio']",https://twitter.com/fortressbio/status/1381922684288765954,False,,0,,,,,,,,[],,,,
1381592980922961920,1381592980922961920,2021-04-12 18:30:10 IST,2021-04-12,18:30:10,+0530,3213634851,fortressbio,Fortress Biotech,,"Lindsay A. Rosenwald, M.D., Fortress' Chairman, President &amp; Chief Executive Officer presents at the 20th Annual Needham Virtual #Healthcare Conference today at 4:30 p.m. ET. A webcast of the presentation will be available on the Events page of our site:  https://t.co/Sqti3yxhGs",en,[],['http://www.fortressbiotech.com'],[],1,1,2,['healthcare'],[],https://twitter.com/fortressbio/status/1381592980922961920,False,,0,,,,,,,,[],,,,
1380254624872009732,1380254624872009732,2021-04-09 01:52:01 IST,2021-04-09,01:52:01,+0530,3213634851,fortressbio,Fortress Biotech,,"In part 2 of his interview with @OutsourcedPharm, @Mustang_Bio Chief Technology Officer, Knut Niss, provides 4 tips for cell-and-gene therapy developers.  https://t.co/GKp9VVNgib $MBIO $FBIO #genetherapy",en,"[{'screen_name': 'outsourcedpharm', 'name': 'outsourced pharma', 'id': '4517272103'}, {'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}]",['https://bit.ly/2Rl1V6L'],[],0,0,2,['genetherapy'],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1380254624872009732,False,,0,,,,,,,,[],,,,
1379801981234077698,1379801980126826498,2021-04-07 19:53:22 IST,2021-04-07,19:53:22,+0530,3213634851,fortressbio,Fortress Biotech,,A webcast of the company’s presentation will be available on the Events page under the News &amp; Media section of Fortress’ website:  https://t.co/Sqti3yxhGs for approximately 30 days following the presentation. $FBIO,en,[],['http://www.fortressbiotech.com'],[],0,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1379801981234077698,False,,0,,,,,,,,[],,,,
1379801980126826498,1379801980126826498,2021-04-07 19:53:22 IST,2021-04-07,19:53:22,+0530,3213634851,fortressbio,Fortress Biotech,,"Fortress Biotech will present at the 20th Annual Needham Virtual #Healthcare Conference on Monday, April 12, 2021, at 4:30 p.m. ET and will also participate in one-on-one meetings during the conference.  https://t.co/uyEndfwHm0 $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/345/fortress-biotech-to-participate-in-the-20th-annual-needham'],[],1,0,0,['healthcare'],['fbio'],https://twitter.com/fortressbio/status/1379801980126826498,False,,0,,,,,,,,[],,,,
1379033761413795840,1379033761413795840,2021-04-05 17:00:44 IST,2021-04-05,17:00:44,+0530,3213634851,fortressbio,Fortress Biotech,,Journey Medical Corporation Enters $7.5 Million Line of Credit Agreement with East West Bank  https://t.co/yTRMYCHFU6,en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/344/journey-medical-corporation-enters-7-5-million-line-of'],[],0,0,1,[],[],https://twitter.com/fortressbio/status/1379033761413795840,False,,0,,,,,,,,[],,,,
1377633212860620802,1377633211803693058,2021-04-01 20:15:27 IST,2021-04-01,20:15:27,+0530,3213634851,fortressbio,Fortress Biotech,,The transaction is expected to close early in the second quarter of this year. QBREXZA (glycopyrronium) generated $24 million in net sales in the U.S. in 2020. Read more:  https://t.co/MeHMi5c7UG $FBIO $LLY,en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/343/journey-medical-corporation-enters-into-a-definitive'],[],0,0,2,[],"['fbio', 'lly']",https://twitter.com/fortressbio/status/1377633212860620802,False,,0,,,,,,,,[],,,,
1377633211803693058,1377633211803693058,2021-04-01 20:15:27 IST,2021-04-01,20:15:27,+0530,3213634851,fortressbio,Fortress Biotech,,"Journey Medical, a partner company of Fortress Biotech, announced that it has entered into a definitive agreement to acquire QBREXZA (glycopyrronium) in the U.S. from @DermiraInc, a wholly-owned subsidiary of @LillyPad.  https://t.co/MeHMi5c7UG $FBIO $LLY",en,"[{'screen_name': 'dermirainc', 'name': 'dermira inc', 'id': '905819336031354880'}, {'screen_name': 'lillypad', 'name': 'eli lilly and company', 'id': '172496840'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/343/journey-medical-corporation-enters-into-a-definitive'],[],1,0,2,[],"['fbio', 'lly']",https://twitter.com/fortressbio/status/1377633211803693058,False,,0,,,,,,,,[],,,,
1377631464855060484,1377631460753031168,2021-04-01 20:08:31 IST,2021-04-01,20:08:31,+0530,3213634851,fortressbio,Fortress Biotech,,Fortress and our partner companies have built a growing portfolio of 7 marketed #dermatologic pharmaceutical products and more than 25 product candidates in our pipeline across multiple #therapeutic categories. Read more:  https://t.co/YsAmPMMGwa $FBIO,en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/342/fortress-biotech-reports-record-2020-financial-results-and'],[],0,0,0,"['dermatologic', 'therapeutic']",['fbio'],https://twitter.com/fortressbio/status/1377631464855060484,False,,0,,,,,,,,[],,,,
1377631463785558016,1377631460753031168,2021-04-01 20:08:30 IST,2021-04-01,20:08:30,+0530,3213634851,fortressbio,Fortress Biotech,,"Additionally, revenue from our marketed #dermatology products increased 28% for full-year 2020, demonstrating the resilience of the Fortress business model during the pandemic.  https://t.co/YsAmPMMGwa $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/342/fortress-biotech-reports-record-2020-financial-results-and'],[],1,0,1,['dermatology'],['fbio'],https://twitter.com/fortressbio/status/1377631463785558016,False,,0,,,,,,,,[],,,,
1377631462816632838,1377631460753031168,2021-04-01 20:08:30 IST,2021-04-01,20:08:30,+0530,3213634851,fortressbio,Fortress Biotech,,"A rolling New Drug Application (""NDA"") submission to the FDA for CUTX-101 for the treatment of #Menkes disease is expected to begin later this year. More info:  https://t.co/YsAmPMMGwa $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/342/fortress-biotech-reports-record-2020-financial-results-and'],[],1,0,1,['menkes'],['fbio'],https://twitter.com/fortressbio/status/1377631462816632838,False,,0,,,,,,,,[],,,,
1377631461742931970,1377631460753031168,2021-04-01 20:08:30 IST,2021-04-01,20:08:30,+0530,3213634851,fortressbio,Fortress Biotech,,"Notably, in February 2021 Fortress partner company, Cyprium Therapeutics, and Sentynl Therapeutics, a wholly-owned subsidiary of the Zydus Group, signed a Development and Asset Purchase Agreement for CUTX-101 for the treatment of #Menkes disease.  https://t.co/YsAmPMMGwa $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/342/fortress-biotech-reports-record-2020-financial-results-and'],[],1,0,0,['menkes'],['fbio'],https://twitter.com/fortressbio/status/1377631461742931970,False,,0,,,,,,,,[],,,,
1377631460753031168,1377631460753031168,2021-04-01 20:08:30 IST,2021-04-01,20:08:30,+0530,3213634851,fortressbio,Fortress Biotech,,"Fortress Biotech announced financial results and recent corporate highlights for the full-year ended December 31, 2020.  https://t.co/YsAmPMMGwa $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/342/fortress-biotech-reports-record-2020-financial-results-and'],[],1,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1377631460753031168,False,,0,,,,,,,,[],,,,
1377601858445979650,1377601858445979650,2021-04-01 18:10:52 IST,2021-04-01,18:10:52,+0530,3213634851,fortressbio,Fortress Biotech,,Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights  https://t.co/LV72r0yy8T $FBIO,en,[],['https://bit.ly/3dnYO5b'],[],0,0,1,[],['fbio'],https://twitter.com/fortressbio/status/1377601858445979650,False,,0,,,,,,,,[],,,,
1374821498582601729,1374821498582601729,2021-03-25 02:02:42 IST,2021-03-25,02:02:42,+0530,3213634851,fortressbio,Fortress Biotech,,Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights  https://t.co/AgrprArpil $MBIO $FBIO,en,[],['https://bit.ly/3foGD2b'],[],0,0,4,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1374821498582601729,False,,0,,,,,,,,[],,,,
1374707612089004032,1374707612089004032,2021-03-24 18:30:10 IST,2021-03-24,18:30:10,+0530,3213634851,fortressbio,Fortress Biotech,,"Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer of Fortress comments on Journey Medical expanding its portfolio of branded dermatology products.  https://t.co/z246aK0W4J $FBIO",en,[],['https://bit.ly/3lGA4J2'],[],0,0,3,[],['fbio'],https://twitter.com/fortressbio/status/1374707612089004032,False,,0,,,,,,,,[],,,,
1374450906306027521,1374450906306027521,2021-03-24 01:30:06 IST,2021-03-24,01:30:06,+0530,3213634851,fortressbio,Fortress Biotech,,".@Mustang_Bio Chief Technology Officer, Knut Niss, spoke with @OutsourcedPharm and provided advice to the cell therapy biopharma community based on the company's accomplishments. Read part 1 of his conversation here:  https://t.co/EddAPrUH1A  $MBIO $FBIO",en,"[{'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}, {'screen_name': 'outsourcedpharm', 'name': 'outsourced pharma', 'id': '4517272103'}]",['https://bit.ly/31aBSAH'],[],0,0,2,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1374450906306027521,False,,0,,,,,,,,[],,,,
1374058749959213063,1374058749959213063,2021-03-22 23:31:49 IST,2021-03-22,23:31:49,+0530,3213634851,fortressbio,Fortress Biotech,,"Journey Medical, a partner company of Fortress Biotech has in-licensed and launched an oral isotretinoin under the brand name Accutane® (isotretinoin capsules USP) in the U.S. Accutane is Journey Medical’s 6th marketed dermatology product. Read more:  https://t.co/z246aK0W4J $FBIO",en,[],['https://bit.ly/3lGA4J2'],[],0,0,3,[],['fbio'],https://twitter.com/fortressbio/status/1374058749959213063,False,,0,,,,,,,,[],,,,
1371891274786177033,1371891274786177033,2021-03-16 23:59:03 IST,2021-03-16,23:59:03,+0530,3213634851,fortressbio,Fortress Biotech,,The webcast of our fireside chat at the Virtual 33rd Annual ROTH Conference is now available for viewing on our website and will be available for approximately 30 days.  https://t.co/Sqti3yxhGs $FBIO,en,[],['http://www.fortressbiotech.com'],[],0,0,1,[],['fbio'],https://twitter.com/fortressbio/status/1371891274786177033,False,,0,,,,,,,,[],,,,
1370026799174840326,1370026799174840326,2021-03-11 20:30:17 IST,2021-03-11,20:30:17,+0530,3213634851,fortressbio,Fortress Biotech,,"Our CEO Lindsay A. Rosenwald, M.D. will be providing a company update at @BarclaysIB’s virtual 2021 #BarcHealthcare Conference today at 3:00 p.m. ET.  https://t.co/K4Ds9LlLxR",en,"[{'screen_name': 'barclaysib', 'name': 'barclays investment bank', 'id': '856524819948609536'}]",[],['https://pbs.twimg.com/media/EwNQGynUUAABHee.jpg'],0,0,0,['barchealthcare'],[],https://twitter.com/fortressbio/status/1370026799174840326,False,,1,https://pbs.twimg.com/media/EwNQGynUUAABHee.jpg,,,,,,,[],,,,
1369409787834798087,1369409786874363905,2021-03-10 03:38:30 IST,2021-03-10,03:38:30,+0530,3213634851,fortressbio,Fortress Biotech,,"Highlights include solidifying the registration path for cosibelimab in metastatic cutaneous squamous cell carcinoma (#mCSCC), as well as announcing positive interim data from the pivotal Phase 1 program. Read more:  https://t.co/1KiA5LwACJ $CKPT $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/339/checkpoint-therapeutics-reports-full-year-2020-financial'],[],0,0,1,['mcscc'],"['ckpt', 'fbio']",https://twitter.com/fortressbio/status/1369409787834798087,False,,0,,,,,,,,[],,,,
1369409786874363905,1369409786874363905,2021-03-10 03:38:30 IST,2021-03-10,03:38:30,+0530,3213634851,fortressbio,Fortress Biotech,,"Checkpoint Therapeutics announced financial results for the full-year ended December 31, 2020 and recent corporate highlights.  https://t.co/1KiA5LwACJ $CKPT $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/339/checkpoint-therapeutics-reports-full-year-2020-financial'],[],2,0,2,[],"['ckpt', 'fbio']",https://twitter.com/fortressbio/status/1369409786874363905,False,,0,,,,,,,,[],,,,
1369260436017868804,1369260436017868804,2021-03-09 17:45:02 IST,2021-03-09,17:45:02,+0530,3213634851,fortressbio,Fortress Biotech,,Our presentation from the @HCWCO Global Life Sciences Virtual Conference is now available for on-demand viewing on our website and will remain available on the Events page for approximately 30 days.  https://t.co/Sqti3yxhGs $FBIO,en,"[{'screen_name': 'hcwco', 'name': 'h.c. wainwright & co.', 'id': '834417067914838016'}]",['http://www.fortressbiotech.com'],[],0,0,2,[],['fbio'],https://twitter.com/fortressbio/status/1369260436017868804,False,,0,,,,,,,,[],,,,
1368972575141945345,1368972575141945345,2021-03-08 22:41:10 IST,2021-03-08,22:41:10,+0530,3213634851,fortressbio,Fortress Biotech,,".@Benzinga highlights our differentiated three-step business model for identifying, developing, and monetizing novel therapies in several large-market therapeutic areas. Find out more about our diversified pipeline here:  https://t.co/yQmIwepbIx $FBIO",en,"[{'screen_name': 'benzinga', 'name': 'benzinga', 'id': '44060322'}]",['https://www.benzinga.com/general/biotech/21/02/19797039/fortress-biotech-ceo-explains-the-companys-three-step-business-model'],[],0,0,3,[],['fbio'],https://twitter.com/fortressbio/status/1368972575141945345,False,,0,,,,,,,,[],,,,
1367565559253110792,1367565559253110792,2021-03-05 01:30:12 IST,2021-03-05,01:30:12,+0530,3213634851,fortressbio,Fortress Biotech,,Checkpoint Therapeutics recently announced the formation of an independent Scientific Advisory Board including preeminent clinical and scientific thought leaders in #oncology. More info:  https://t.co/WHF6ODiYKx $CKPT $FBIO,en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/335/checkpoint-therapeutics-announces-formation-of-scientific'],[],0,0,2,['oncology'],"['ckpt', 'fbio']",https://twitter.com/fortressbio/status/1367565559253110792,False,,0,,,,,,,,[],,,,
1367483293780819981,1367483293780819981,2021-03-04 20:03:18 IST,2021-03-04,20:03:18,+0530,3213634851,fortressbio,Fortress Biotech,,"Checkpoint Therapeutics President and CEO, James Oliviero, will participate in the @HCWCO Global Life Sciences Virtual Conference. The presentation will be available on-demand on the Company's website beginning on March 9, 2021, at 7 a.m. ET.  https://t.co/4oYLNWVqVE $CKPT $FBIO",en,"[{'screen_name': 'hcwco', 'name': 'h.c. wainwright & co.', 'id': '834417067914838016'}]",['https://bit.ly/3rtwjsw'],[],0,1,3,[],"['ckpt', 'fbio']",https://twitter.com/fortressbio/status/1367483293780819981,False,,0,,,,,,,,[],,,,
1367482759518822402,1367482759518822402,2021-03-04 20:01:11 IST,2021-03-04,20:01:11,+0530,3213634851,fortressbio,Fortress Biotech,,".@Mustang_Bio will participate in three virtual #investor conferences in March 2021: @HCWCO Global Life Sciences Virtual Conference, Oppenheimer 31st Annual Virtual Healthcare Conference, and Redburn Virtual #GeneTherapy Summit. More info:  https://t.co/n33HftuBmB $MBIO $FBIO",en,"[{'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}, {'screen_name': 'hcwco', 'name': 'h.c. wainwright & co.', 'id': '834417067914838016'}]",['https://bit.ly/3uT81KS'],[],0,0,0,"['investor', 'genetherapy']","['mbio', 'fbio']",https://twitter.com/fortressbio/status/1367482759518822402,False,,0,,,,,,,,[],,,,
1367461832580096002,1367461828259962924,2021-03-04 18:38:01 IST,2021-03-04,18:38:01,+0530,3213634851,fortressbio,Fortress Biotech,,"Oppenheimer 31st Annual Virtual Healthcare Conference: The company will present on Thursday, March 18, 2021, at 10:40 a.m. ET and will participate in one-on-one meetings during the conference.  https://t.co/OAydtyKMr6 $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/338/fortress-biotech-to-participate-in-four-march-2021-virtual'],[],0,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1367461832580096002,False,,0,,,,,,,,[],,,,
1367461831468605446,1367461828259962924,2021-03-04 18:38:01 IST,2021-03-04,18:38:01,+0530,3213634851,fortressbio,Fortress Biotech,,"Virtual 33rd Annual ROTH Conference: The company will participate in a fireside chat on March 16, 2021, at 11 AM ET and attend 1-on-1 meetings during the conference. A webcast will be available on the Events page of Fortress’ website after the chat:  https://t.co/OAydtyKMr6 $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/338/fortress-biotech-to-participate-in-four-march-2021-virtual'],[],1,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1367461831468605446,False,,0,,,,,,,,[],,,,
1367461830424211457,1367461828259962924,2021-03-04 18:38:01 IST,2021-03-04,18:38:01,+0530,3213634851,fortressbio,Fortress Biotech,,"Barclays Global Healthcare Virtual Conference: The company will present on Thursday, March 11, 2021, at 3:00 p.m. ET and will participate in one-on-one meetings during the conference.  https://t.co/OAydtyKMr6 $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/338/fortress-biotech-to-participate-in-four-march-2021-virtual'],[],1,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1367461830424211457,False,,0,,,,,,,,[],,,,
1367461829279121409,1367461828259962924,2021-03-04 18:38:00 IST,2021-03-04,18:38:00,+0530,3213634851,fortressbio,Fortress Biotech,,".@HCWCO Global Life Sciences Virtual Conference: The company’s presentation will be available for on-demand viewing on Fortress’ website beginning on March 9, 2021, at 7:00 a.m. ET and will remain available on the Events page for approx. 30 days.  https://t.co/OAydtyKMr6 $FBIO",en,"[{'screen_name': 'hcwco', 'name': 'h.c. wainwright & co.', 'id': '834417067914838016'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/338/fortress-biotech-to-participate-in-four-march-2021-virtual'],[],1,0,1,[],['fbio'],https://twitter.com/fortressbio/status/1367461829279121409,False,,0,,,,,,,,[],,,,
1367461828259962924,1367461828259962924,2021-03-04 18:38:00 IST,2021-03-04,18:38:00,+0530,3213634851,fortressbio,Fortress Biotech,,"Fortress Biotech announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in four virtual #investor conferences in March 2021.   https://t.co/OAydtyKMr6 $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/338/fortress-biotech-to-participate-in-four-march-2021-virtual'],[],1,0,1,['investor'],['fbio'],https://twitter.com/fortressbio/status/1367461828259962924,False,,0,,,,,,,,[],,,,
1367242669752160256,1367242663418683393,2021-03-04 04:07:09 IST,2021-03-04,04:07:09,+0530,3213634851,fortressbio,Fortress Biotech,,Cyprium will retain 100% ownership over any FDA priority review voucher that may be issued at NDA approval for CUTX-101. Read more:  https://t.co/mfcXvyzD2i $FBIO,en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/331/cyprium-therapeutics-a-fortress-biotech-partner-company'],[],0,0,3,[],['fbio'],https://twitter.com/fortressbio/status/1367242669752160256,False,,0,,,,,,,,[],,,,
1367242668485451776,1367242663418683393,2021-03-04 04:07:08 IST,2021-03-04,04:07:08,+0530,3213634851,fortressbio,Fortress Biotech,,Continued development of CUTX-101 will be overseen by a Joint Steering Committee consisting of representatives from Cyprium and Sentynl.  https://t.co/mfcXvyzD2i $FBIO,en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/331/cyprium-therapeutics-a-fortress-biotech-partner-company'],[],1,0,2,[],['fbio'],https://twitter.com/fortressbio/status/1367242668485451776,False,,0,,,,,,,,[],,,,
1367242667298418691,1367242663418683393,2021-03-04 04:07:08 IST,2021-03-04,04:07:08,+0530,3213634851,fortressbio,Fortress Biotech,,"Cyprium will retain development responsibility of CUTX-101 through approval of the NDA by the U.S. Food and Drug Administration, and Sentynl will be responsible for commercialization of CUTX-101 as well as progressing newborn screening activities.  https://t.co/mfcXvyzD2i $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/331/cyprium-therapeutics-a-fortress-biotech-partner-company'],[],1,0,1,[],['fbio'],https://twitter.com/fortressbio/status/1367242667298418691,False,,0,,,,,,,,[],,,,
1367242666056900614,1367242663418683393,2021-03-04 04:07:08 IST,2021-03-04,04:07:08,+0530,3213634851,fortressbio,Fortress Biotech,,"Under the terms of the agreement, Cyprium will receive up to $20M upfront development and regulatory cash payments and royalties &amp; commercial milestone payments based on the net sales of CUTX-101.  https://t.co/mfcXvyzD2i $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/331/cyprium-therapeutics-a-fortress-biotech-partner-company'],[],1,0,1,[],['fbio'],https://twitter.com/fortressbio/status/1367242666056900614,False,,0,,,,,,,,[],,,,
1367242664786075650,1367242663418683393,2021-03-04 04:07:08 IST,2021-03-04,04:07:08,+0530,3213634851,fortressbio,Fortress Biotech,,CUTX-101 is Cyprium's Copper Histidinate product candidate for the treatment of #Menkes disease.  https://t.co/mfcXvyzD2i $FBIO,en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/331/cyprium-therapeutics-a-fortress-biotech-partner-company'],[],1,0,1,['menkes'],['fbio'],https://twitter.com/fortressbio/status/1367242664786075650,False,,0,,,,,,,,[],,,,
1367242663418683393,1367242663418683393,2021-03-04 04:07:07 IST,2021-03-04,04:07:07,+0530,3213634851,fortressbio,Fortress Biotech,,"Cyprium Therapeutics, Inc., a Fortress Biotech, Inc. partner company, &amp; Sentynl Therapeutics, Inc., recently announced the execution of an asset purchase agreement to commit development funding for and acquire Cyprium’s proprietary rights to CUTX-101  https://t.co/mfcXvyzD2i $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/331/cyprium-therapeutics-a-fortress-biotech-partner-company'],[],1,0,3,[],['fbio'],https://twitter.com/fortressbio/status/1367242663418683393,False,,0,,,,,,,,[],,,,
1366400199061499906,1366400197778145286,2021-03-01 20:19:28 IST,2021-03-01,20:19:28,+0530,3213634851,fortressbio,Fortress Biotech,,"Checkpoint's newly announced SAB will work closely with Company leadership to further develop Checkpoint's novel treatments for patients with solid tumor cancers, including cosibelimab and CK-101.  https://t.co/WHF6OD1nlX $CKPT $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/335/checkpoint-therapeutics-announces-formation-of-scientific'],[],0,1,1,[],"['ckpt', 'fbio']",https://twitter.com/fortressbio/status/1366400199061499906,False,,0,,,,,,,,[],,,,
1366400197778145286,1366400197778145286,2021-03-01 20:19:28 IST,2021-03-01,20:19:28,+0530,3213634851,fortressbio,Fortress Biotech,,"Checkpoint Therapeutics announced the formation of an independent Scientific Advisory Board comprising leaders in the fields of #immunotherapy, lung and skin cancers.  Read more:  https://t.co/WHF6ODiYKx $CKPT $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/335/checkpoint-therapeutics-announces-formation-of-scientific'],[],1,0,2,['immunotherapy'],"['ckpt', 'fbio']",https://twitter.com/fortressbio/status/1366400197778145286,False,,0,,,,,,,,[],,,,
1366399384469073923,1366399384469073923,2021-03-01 20:16:14 IST,2021-03-01,20:16:14,+0530,3213634851,fortressbio,Fortress Biotech,,.@CaelumBio announced its collaboration with and support of the amyloidosis advocacy community as Amyloidosis Awareness Month begins. For more information:  https://t.co/RpjGKgXFQO $FBIO,en,"[{'screen_name': 'caelumbio', 'name': 'caelum biosciences', 'id': '818949710346129408'}]",['https://bit.ly/2ZYssI9'],[],0,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1366399384469073923,False,,0,,,,,,,,[],,,,
1366081367444979720,1366081357940686850,2021-02-28 23:12:33 IST,2021-02-28,23:12:33,+0530,3213634851,fortressbio,Fortress Biotech,,".@MustangBio is developing CD123, an adaptive cellular #immunotherapy for patients with AML and BPDCN. Learn more:  https://t.co/APBDo0yns9 #BloodCancer #RareDiseaseDay",en,"[{'screen_name': 'mustangbio', 'name': 'gianna sargent', 'id': '762677342980415488'}]",['https://www.mustangbio.com/pipeline/'],[],0,0,0,"['immunotherapy', 'bloodcancer', 'rarediseaseday']",[],https://twitter.com/fortressbio/status/1366081367444979720,False,,0,,,,,,,,[],,,,
1366081364752289793,1366081357940686850,2021-02-28 23:12:32 IST,2021-02-28,23:12:32,+0530,3213634851,fortressbio,Fortress Biotech,,".@MustangBio is developing MB-107/MB-207 for the treatment of infants with #XSCID, also known as bubble boy disease, and has partnered with @StJude to conduct the world’s first lentiviral gene therapy trial for #XSCID. Learn more:  https://t.co/APBDo0yns9 #RareDiseaseDay",en,"[{'screen_name': 'mustangbio', 'name': 'gianna sargent', 'id': '762677342980415488'}, {'screen_name': 'stjude', 'name': 'st. jude', 'id': '9624042'}]",['https://www.mustangbio.com/pipeline/'],[],1,0,1,"['xscid', 'xscid', 'rarediseaseday']",[],https://twitter.com/fortressbio/status/1366081364752289793,False,,0,,,,,,,,[],,,,
1366081362046963713,1366081357940686850,2021-02-28 23:12:31 IST,2021-02-28,23:12:31,+0530,3213634851,fortressbio,Fortress Biotech,,".@CaelumBio is dedicated to developing treatments for rare and life-threatening conditions, including its lead candidate CAEL-101, a novel antibody that is being developed for patients with #ALAmyloidosis. Find out more:  https://t.co/Bws4eWi5ag #RareDiseaseDay",en,"[{'screen_name': 'caelumbio', 'name': 'caelum biosciences', 'id': '818949710346129408'}]",['https://www.caelumbio.com'],[],1,0,1,"['alamyloidosis', 'rarediseaseday']",[],https://twitter.com/fortressbio/status/1366081362046963713,False,,0,,,,,,,,[],,,,
1366081359605817345,1366081357940686850,2021-02-28 23:12:31 IST,2021-02-28,23:12:31,+0530,3213634851,fortressbio,Fortress Biotech,,"Cyprium Therapeutics is focused on the development of novel therapies for the treatment of Menkes disease, a rare X-linked pediatric disease caused by gene mutations of copper transporter ATP7A, and related copper metabolism disorders.  https://t.co/PzBp37AAbw #RareDiseaseDay",en,[],['https://www.cypriumtx.com'],[],1,0,1,['rarediseaseday'],[],https://twitter.com/fortressbio/status/1366081359605817345,False,,0,,,,,,,,[],,,,
1366081357940686850,1366081357940686850,2021-02-28 23:12:30 IST,2021-02-28,23:12:30,+0530,3213634851,fortressbio,Fortress Biotech,,"Fortress, in partnership with Cyprium Therapeutics, @CaelumBio, and @Mustang_Bio, is dedicated to the development of therapies for patients with #rarediseases. Learn more:  https://t.co/F5sB1M5wEe #RareDiseaseDay #MenkesDisease  #ALAmyloidosis #XSCID #Bubbleboydisease #AML #BPDCN",en,"[{'screen_name': 'caelumbio', 'name': 'caelum biosciences', 'id': '818949710346129408'}, {'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}]",['https://www.fortressbiotech.com/programs'],[],1,1,1,"['rarediseases', 'rarediseaseday', 'menkesdisease', 'alamyloidosis', 'xscid', 'bubbleboydisease', 'aml', 'bpdcn']",[],https://twitter.com/fortressbio/status/1366081357940686850,False,,0,,,,,,,,[],,,,
1365376127913631750,1365376127913631750,2021-02-27 00:30:11 IST,2021-02-27,00:30:11,+0530,3213634851,fortressbio,Fortress Biotech,,We are proud to be a sponsor of this year's #RareDiseaseDay. Join us on 2/28 to help raise awareness of rare diseases and their impact on patients lives. Learn more here:  https://t.co/dWbVlPFhnL  https://t.co/enGPx7N28Z,en,[],['https://www.rarediseaseday.org'],['https://pbs.twimg.com/media/EvLKWELXAAsVXR8.png'],0,7,9,['rarediseaseday'],[],https://twitter.com/fortressbio/status/1365376127913631750,False,,1,https://pbs.twimg.com/media/EvLKWELXAAsVXR8.png,,,,,,,[],,,,
1365287800883535876,1365287800883535876,2021-02-26 18:39:12 IST,2021-02-26,18:39:12,+0530,3213634851,fortressbio,Fortress Biotech,,.@Mustang_Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®  https://t.co/nUWG9l9ui5 $MBIO $FBIO,en,"[{'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}]",['https://bit.ly/3pWs4V1'],[],0,0,2,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1365287800883535876,False,,0,,,,,,,,[],,,,
1365287445361795075,1365287445361795075,2021-02-26 18:37:47 IST,2021-02-26,18:37:47,+0530,3213634851,fortressbio,Fortress Biotech,,Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®  https://t.co/aGXDMpZ6ab $FBIO,en,[],['https://bit.ly/3aSxr3g'],[],0,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1365287445361795075,False,,0,,,,,,,,[],,,,
1364587573520302082,1364587573520302082,2021-02-24 20:16:44 IST,2021-02-24,20:16:44,+0530,3213634851,fortressbio,Fortress Biotech,,"Cyprium Therapeutics and Sentynl Therapeutics, a Wholly-owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics’ Copper Histidinate Product Candidate for Treatment of Menkes Disease.  https://t.co/qQUJ9qlgKV $FBIO",en,[],['https://bit.ly/3pRqX8U'],[],0,1,0,[],['fbio'],https://twitter.com/fortressbio/status/1364587573520302082,False,,0,,,,,,,,[],,,,
1363863646120652801,1363863641775292419,2021-02-22 20:20:07 IST,2021-02-22,20:20:07,+0530,3213634851,fortressbio,Fortress Biotech,,Aevitas Therapeutics is a Fortress Biotech partner company focused on the development of novel gene therapy approaches for complement-mediated diseasesFor more information:  https://t.co/gBxsFDHCvS $FBIO,en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/330/aevitas-therapeutics-appoints-markus-peters-ph-d-m-sc'],[],0,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1363863646120652801,False,,0,,,,,,,,[],,,,
1363863644992393217,1363863641775292419,2021-02-22 20:20:06 IST,2021-02-22,20:20:06,+0530,3213634851,fortressbio,Fortress Biotech,,"Aevitas also appointed Catherine Bowes Rickman, Ph.D., FARVO, a leading #AMD researcher, to its Scientific Advisory Board (SAB) to support the advancement of its innovative program for the treatment of #dryAMD.  https://t.co/gBxsFDHCvS $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/330/aevitas-therapeutics-appoints-markus-peters-ph-d-m-sc'],[],1,0,0,"['amd', 'dryamd']",['fbio'],https://twitter.com/fortressbio/status/1363863644992393217,False,,0,,,,,,,,[],,,,
1363863643926970373,1363863641775292419,2021-02-22 20:20:06 IST,2021-02-22,20:20:06,+0530,3213634851,fortressbio,Fortress Biotech,,"Dr. Peters will lead Aevitas as it advances its proprietary platform designed to deliver engineered, fully functional, shortened complement factor H (CFH) via adeno-associated virus (AAV).  https://t.co/gBxsFDHCvS $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/330/aevitas-therapeutics-appoints-markus-peters-ph-d-m-sc'],[],1,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1363863643926970373,False,,0,,,,,,,,[],,,,
1363863642932989956,1363863641775292419,2021-02-22 20:20:06 IST,2021-02-22,20:20:06,+0530,3213634851,fortressbio,Fortress Biotech,,Dr. Peters was most recently the Chief Operating Officer of Gemini Therapeutics after serving as the Chief Commercial Officer of Agilis Biotherapeutics.  https://t.co/gBxsFDHCvS $FBIO,en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/330/aevitas-therapeutics-appoints-markus-peters-ph-d-m-sc'],[],1,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1363863642932989956,False,,0,,,,,,,,[],,,,
1363863641775292419,1363863641775292419,2021-02-22 20:20:06 IST,2021-02-22,20:20:06,+0530,3213634851,fortressbio,Fortress Biotech,,"Aevitas Therapeutics announced the appointment of Markus Peters, Ph.D.,  https://t.co/sqbXKCNS9Q., as President and Chief Executive Officer. Read more:  https://t.co/gBxsFDHCvS $FBIO",en,[],"['http://M.Sc', 'https://www.fortressbiotech.com/news-media/press-releases/detail/330/aevitas-therapeutics-appoints-markus-peters-ph-d-m-sc']",[],1,0,1,[],['fbio'],https://twitter.com/fortressbio/status/1363863641775292419,False,,0,,,,,,,,[],,,,
1361692223566397443,1361692223566397443,2021-02-16 20:31:39 IST,2021-02-16,20:31:39,+0530,3213634851,fortressbio,Fortress Biotech,,Did you know that there are more than 25 million Americans living with #rarediseases? Help us raise awareness on Feb 28!  https://t.co/dWbVlPFhnL #RareDiseaseDay  https://t.co/PznHbtz5FW,en,[],['https://www.rarediseaseday.org'],['https://pbs.twimg.com/media/EuWz2kiXYAostjX.png'],1,0,1,"['rarediseases', 'rarediseaseday']",[],https://twitter.com/fortressbio/status/1361692223566397443,False,,1,https://pbs.twimg.com/media/EuWz2kiXYAostjX.png,,,,,,,[],,,,
1361676765010292737,1361676765010292737,2021-02-16 19:30:14 IST,2021-02-16,19:30:14,+0530,3213634851,fortressbio,Fortress Biotech,,Reminder: Fortress will be presenting at The MicroCap Rodeo: Winter Wonderland Conference. For more info and how to register:  https://t.co/V1luBerxJ6 $FBIO,en,[],['https://microcaprodeo.com'],[],0,1,2,[],['fbio'],https://twitter.com/fortressbio/status/1361676765010292737,False,,0,,,,,,,,[],,,,
1358777646830800901,1358777646830800901,2021-02-08 19:30:10 IST,2021-02-08,19:30:10,+0530,3213634851,fortressbio,Fortress Biotech,,"We are looking forward to participating in The MicroCap Rodeo: Winter Wonderland Conference, February 16-19, 2021. Click here for more info:  https://t.co/V1luBerxJ6 $FBIO",en,[],['https://microcaprodeo.com'],[],0,1,1,[],['fbio'],https://twitter.com/fortressbio/status/1358777646830800901,False,,0,,,,,,,,[],,,,
1356958123177746432,1356958123177746432,2021-02-03 19:00:02 IST,2021-02-03,19:00:02,+0530,3213634851,fortressbio,Fortress Biotech,,"Manuel Litchman, M.D., President and Chief Executive Officer of @Mustang_Bio comments on the progress of its lentiviral gene therapies for the treatment of X-linked severe combined immunodeficiency (#XSCID).  https://t.co/J9Pe50XOOJ #MB107 #MB207   $MBIO $FBIO",en,"[{'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}]",['https://bit.ly/2YDA0zm'],[],0,0,1,"['xscid', 'mb107', 'mb207']","['mbio', 'fbio']",https://twitter.com/fortressbio/status/1356958123177746432,False,,0,,,,,,,,[],,,,
1356717044755005441,1356717040585891842,2021-02-03 03:02:04 IST,2021-02-03,03:02:04,+0530,3213634851,fortressbio,Fortress Biotech,,Clinical outcomes in investigator-IND XSCID trials of MB-107 and MB-207 continue to show compelling efficacy. Read more:  https://t.co/cc3KnKB1lA $MBIO $FBIO,en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/329/mustang-bio-provides-updates-on-its-lentiviral-gene'],[],0,0,0,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1356717044755005441,False,,0,,,,,,,,[],,,,
1356717043442147331,1356717040585891842,2021-02-03 03:02:04 IST,2021-02-03,03:02:04,+0530,3213634851,fortressbio,Fortress Biotech,,.@Mustang_Bio will proceed with its plans to initiate the pivotal Phase 2 trial of MB-107 in newly diagnosed XSCID patients and intends to enroll first patient in the second quarter of 2021.  https://t.co/cc3KnKB1lA $MBIO $FBIO,en,"[{'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/329/mustang-bio-provides-updates-on-its-lentiviral-gene'],[],1,0,0,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1356717043442147331,False,,0,,,,,,,,[],,,,
1356717042334892032,1356717040585891842,2021-02-03 03:02:04 IST,2021-02-03,03:02:04,+0530,3213634851,fortressbio,Fortress Biotech,,"On January 28, 2021, the U.S. FDA removed the clinical hold on the MB-107 pivotal Phase 2 clinical trial IND application after reviewing a comprehensive CMC package that was submitted by Mustang in late December 2020.  https://t.co/cc3KnKB1lA $MBIO $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/329/mustang-bio-provides-updates-on-its-lentiviral-gene'],[],1,0,0,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1356717042334892032,False,,0,,,,,,,,[],,,,
1356717040585891842,1356717040585891842,2021-02-03 03:02:03 IST,2021-02-03,03:02:03,+0530,3213634851,fortressbio,Fortress Biotech,,".@Mustang_Bio has provided updates on MB-107 and MB-207, its lentiviral gene therapies for the treatment of X-linked severe combined immunodeficiency (#XSCID), also known as bubble boy disease.  https://t.co/cc3KnKB1lA $MBIO $FBIO",en,"[{'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/329/mustang-bio-provides-updates-on-its-lentiviral-gene'],[],1,0,0,['xscid'],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1356717040585891842,False,,0,,,,,,,,[],,,,
1356581665372590080,1356581665372590080,2021-02-02 18:04:07 IST,2021-02-02,18:04:07,+0530,3213634851,fortressbio,Fortress Biotech,,Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)  https://t.co/J9Pe50XOOJ $MBIO $FBIO,en,[],['https://bit.ly/2YDA0zm'],[],0,2,2,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1356581665372590080,False,,0,,,,,,,,[],,,,
1352262180922667009,1352262180922667009,2021-01-21 20:00:02 IST,2021-01-21,20:00:02,+0530,3213634851,fortressbio,Fortress Biotech,,.@Mustang_Bio's presentation at @BRileyFinancial’s Virtual #Oncology Investor Conference takes place today at 1:30 p.m. EST and will be available to all conference-registered institutional investors. $MBIO $FBIO,en,"[{'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}, {'screen_name': 'brileyfinancial', 'name': 'b. riley financial', 'id': '923539128876240896'}]",[],[],1,0,2,['oncology'],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1352262180922667009,False,,0,,,,,,,,[],,,,
1352254667208724480,1352254667208724480,2021-01-21 19:30:10 IST,2021-01-21,19:30:10,+0530,3213634851,fortressbio,Fortress Biotech,,Checkpoint Therapeutics's presentation at @BRileyFinancial’s Virtual #Oncology Investor Conference takes place today at 10:00 a.m. EST and will be available to all conference-registered institutional investors. $CKPT $FBIO,en,"[{'screen_name': 'brileyfinancial', 'name': 'b. riley financial', 'id': '923539128876240896'}]",[],[],0,0,0,['oncology'],"['ckpt', 'fbio']",https://twitter.com/fortressbio/status/1352254667208724480,False,,0,,,,,,,,[],,,,
1348585465214066688,1348585465214066688,2021-01-11 16:30:05 IST,2021-01-11,16:30:05,+0530,3213634851,fortressbio,Fortress Biotech,,Checkpoint Therapeutics's presentation at the @HCWCO Virtual BioConnect Conference is now available for on-demand viewing on the Company's website:  https://t.co/7iyU9M8Vno $CKPT $FBIO,en,"[{'screen_name': 'hcwco', 'name': 'h.c. wainwright & co.', 'id': '834417067914838016'}]",['https://ir.checkpointtx.com/event-calendar/default.aspx'],[],0,0,2,[],"['ckpt', 'fbio']",https://twitter.com/fortressbio/status/1348585465214066688,False,,0,,,,,,,,[],,,,
1348585463397949441,1348585463397949441,2021-01-11 16:30:04 IST,2021-01-11,16:30:04,+0530,3213634851,fortressbio,Fortress Biotech,,Fortress' presentation at the @HCWCO Virtual BioConnect Conference is now available for on-demand viewing on the Company's website:  https://t.co/Sqti3yxhGs $FBIO,en,"[{'screen_name': 'hcwco', 'name': 'h.c. wainwright & co.', 'id': '834417067914838016'}]",['http://www.fortressbiotech.com'],[],0,1,1,[],['fbio'],https://twitter.com/fortressbio/status/1348585463397949441,False,,0,,,,,,,,[],,,,
1348585462349389825,1348585462349389825,2021-01-11 16:30:04 IST,2021-01-11,16:30:04,+0530,3213634851,fortressbio,Fortress Biotech,,.@Mustang_Bio's presentation at the @HCWCO Virtual BioConnect Conference is now available for on-demand viewing on the Company's website:  https://t.co/MoRh4WbG2l $MBIO $FBIO,en,"[{'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}, {'screen_name': 'hcwco', 'name': 'h.c. wainwright & co.', 'id': '834417067914838016'}]",['http://www.mustangbio.com'],[],0,0,1,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1348585462349389825,False,,0,,,,,,,,[],,,,
1347951300424724481,1347951300424724481,2021-01-09 22:30:08 IST,2021-01-09,22:30:08,+0530,3213634851,fortressbio,Fortress Biotech,,Reminder: Fortress' presentation at the 2021 CTIC 5th Healthcare Investment Digital Summit is today at 8:00 p.m. EST.  https://t.co/fa6ysIssWo $FBIO,en,[],['https://ctic-conferences.com'],[],0,1,1,[],['fbio'],https://twitter.com/fortressbio/status/1347951300424724481,False,,0,,,,,,,,[],,,,
1346820708438056961,1346820708438056961,2021-01-06 19:37:34 IST,2021-01-06,19:37:34,+0530,3213634851,fortressbio,Fortress Biotech,,"Checkpoint Therapeutics announced that James Oliviero, President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021. Event details can be found here:   https://t.co/I8gskY7dpw $CKPT $FBIO",en,[],['https://bit.ly/35fcf42'],[],0,0,2,[],"['ckpt', 'fbio']",https://twitter.com/fortressbio/status/1346820708438056961,False,,0,,,,,,,,[],,,,
1346453177047117824,1346453177047117824,2021-01-05 19:17:07 IST,2021-01-05,19:17:07,+0530,3213634851,fortressbio,Fortress Biotech,,".@Mustang_Bio announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021. Event details can be found here:  https://t.co/994kbLNxep $MBIO $FBIO",en,"[{'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}]",['https://bit.ly/2JOKvfm'],[],0,0,1,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1346453177047117824,False,,0,,,,,,,,[],,,,
1346452557246439424,1346452554398511104,2021-01-05 19:14:40 IST,2021-01-05,19:14:40,+0530,3213634851,fortressbio,Fortress Biotech,,.@HCWCO Virtual BioConnect Conference: The company’s presentation will be available on-demand on Fortress’ website beginning Monday 1/11 at 6 a.m. EST and will remain available on the Events page for approximately 30 days following the presentation.  https://t.co/Sqti3yxhGs $FBIO,en,"[{'screen_name': 'hcwco', 'name': 'h.c. wainwright & co.', 'id': '834417067914838016'}]",['http://www.fortressbiotech.com'],[],0,0,1,[],['fbio'],https://twitter.com/fortressbio/status/1346452557246439424,False,,0,,,,,,,,[],,,,
1346452556411711489,1346452554398511104,2021-01-05 19:14:39 IST,2021-01-05,19:14:39,+0530,3213634851,fortressbio,Fortress Biotech,,"2021 CTIC 5th Healthcare Investment Digital Summit: The company will present on Saturday, January 9, 2021, at 8:00 p.m. EST. $FBIO",en,[],[],[],1,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1346452556411711489,False,,0,,,,,,,,[],,,,
1346452555438714883,1346452554398511104,2021-01-05 19:14:39 IST,2021-01-05,19:14:39,+0530,3213634851,fortressbio,Fortress Biotech,,"10th Annual @LifeSciAdvisors Corporate Access Event: The company will host virtual one-on-one meetings during the conference on Wednesday, January 6 through Friday, January 8 and Monday, January 11 through Thursday, January 14, 2021. $FBIO",en,"[{'screen_name': 'lifesciadvisors', 'name': 'lifesci advisors', 'id': '281648605'}]",[],[],1,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1346452555438714883,False,,0,,,,,,,,[],,,,
1346452554398511104,1346452554398511104,2021-01-05 19:14:39 IST,2021-01-05,19:14:39,+0530,3213634851,fortressbio,Fortress Biotech,,"Fortress Biotech announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021. Details of the events are as follows (Thread):   https://t.co/oTHOzNQVL0 $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/326/fortress-biotech-to-participate-in-three-january-2021'],[],1,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1346452554398511104,False,,0,,,,,,,,[],,,,
1341020804901965826,1341020802876108802,2020-12-21 19:30:49 IST,2020-12-21,19:30:49,+0530,3213634851,fortressbio,Fortress Biotech,,"The Ph. 1 MB-101 trial will enroll up to 30 patients and take place at @cityofhope, where the chimeric antigen receptor T (CAR T) cell therapy was initially developed. For additional information about the trial:  https://t.co/vj3TbGKd8j $MBIO $FBIO",en,"[{'screen_name': 'cityofhope', 'name': 'city of hope', 'id': '19631946'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/325/mustang-bio-and-city-of-hope-announce-initiation-of-phase-1'],[],0,0,1,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1341020804901965826,False,,0,,,,,,,,[],,,,
1341020803933089795,1341020802876108802,2020-12-21 19:30:49 IST,2020-12-21,19:30:49,+0530,3213634851,fortressbio,Fortress Biotech,,"Leptomeningeal brain tumors include #glioblastoma, #ependymoma and #medulloblastoma. More info:  https://t.co/vj3TbGKd8j $MBIO $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/325/mustang-bio-and-city-of-hope-announce-initiation-of-phase-1'],[],1,0,2,"['glioblastoma', 'ependymoma', 'medulloblastoma']","['mbio', 'fbio']",https://twitter.com/fortressbio/status/1341020803933089795,False,,0,,,,,,,,[],,,,
1341020802876108802,1341020802876108802,2020-12-21 19:30:49 IST,2020-12-21,19:30:49,+0530,3213634851,fortressbio,Fortress Biotech,,".@Mustang_Bio &amp; @cityofhope have announced that a Ph. 1 single-center, two-arm clinical trial has been initiated to establish the safety &amp; feasibility of MB-101 (autologous IL13Rα2-CAR T cells) in patients with leptomeningeal brain tumors.  https://t.co/vj3TbGKd8j $MBIO $FBIO",en,"[{'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}, {'screen_name': 'cityofhope', 'name': 'city of hope', 'id': '19631946'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/325/mustang-bio-and-city-of-hope-announce-initiation-of-phase-1'],[],1,0,2,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1341020802876108802,False,,0,,,,,,,,[],,,,
1339975023180865540,1339975021092102148,2020-12-18 22:15:15 IST,2020-12-18,22:15:15,+0530,3213634851,fortressbio,Fortress Biotech,,“Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis” is available here:  https://t.co/PotFh1MYPu,en,[],['https://www.sciencedirect.com/science/article/pii/S0376871620305329?via%3Dihub'],[],0,0,0,[],[],https://twitter.com/fortressbio/status/1339975023180865540,False,,0,,,,,,,,[],,,,
1339975022161629185,1339975021092102148,2020-12-18 22:15:15 IST,2020-12-18,22:15:15,+0530,3213634851,fortressbio,Fortress Biotech,,"In this study, data from the RADARS® System’s Survey of NMURx Program online cross-sectional general population national surveys are analyzed from 2018 from Germany, Italy, Spain, and the UK, with 45K total responses. More info:  https://t.co/dGeco3r9g6 $ATXI $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/323/avenue-therapeutics-announces-publication-of-tramadol'],[],1,0,0,[],"['atxi', 'fbio']",https://twitter.com/fortressbio/status/1339975022161629185,False,,0,,,,,,,,[],,,,
1339975021092102148,1339975021092102148,2020-12-18 22:15:15 IST,2020-12-18,22:15:15,+0530,3213634851,fortressbio,Fortress Biotech,,.@AvenueThera announced that a publication titled “Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis” has been published in Drug and Alcohol Dependence. Read more:  https://t.co/dGeco3r9g6 $ATXI $FBIO,en,"[{'screen_name': 'avenuethera', 'name': 'avenue therapeutics', 'id': '917381549213044737'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/323/avenue-therapeutics-announces-publication-of-tramadol'],[],1,0,0,[],"['atxi', 'fbio']",https://twitter.com/fortressbio/status/1339975021092102148,False,,0,,,,,,,,[],,,,
1339974598687911936,1339974595391188995,2020-12-18 22:13:34 IST,2020-12-18,22:13:34,+0530,3213634851,fortressbio,Fortress Biotech,,"The objective of the study was to evaluate nonmedical use and diversion of tramadol and comparator opioids (morphine, oxycodone, and hydrocodone) using real-world data from the Addiction Severity Index‒Multimedia Version (ASI-MV®). More info:  https://t.co/xqXF8OjH8X $ATXI $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/324/avenue-therapeutics-announces-publication-of-real-world'],[],0,0,0,[],"['atxi', 'fbio']",https://twitter.com/fortressbio/status/1339974598687911936,False,,0,,,,,,,,[],,,,
1339974596842287111,1339974595391188995,2020-12-18 22:13:34 IST,2020-12-18,22:13:34,+0530,3213634851,fortressbio,Fortress Biotech,,The publication titled “Real-World Data on Nonmedical Use of Tramadol from Patients Evaluated for Substance Abuse Treatment in the NAVIPPRO Addiction Severity Index‒Multimedia Version (ASI-MV®) Network” is available here:  https://t.co/x0Ljy77COs $ATXI $FBIO,en,[],['https://www.springer.com/journal/40264'],[],1,0,0,[],"['atxi', 'fbio']",https://twitter.com/fortressbio/status/1339974596842287111,False,,0,,,,,,,,[],,,,
1339974595391188995,1339974595391188995,2020-12-18 22:13:33 IST,2020-12-18,22:13:33,+0530,3213634851,fortressbio,Fortress Biotech,,.@AvenueThera announced the publication of real-world data on nonmedical use (NMU) of tramadol in the ASI-MV network in Drug Safety. Read more:  https://t.co/xqXF8OjH8X $ATXI $FBIO,en,"[{'screen_name': 'avenuethera', 'name': 'avenue therapeutics', 'id': '917381549213044737'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/324/avenue-therapeutics-announces-publication-of-real-world'],[],1,0,0,[],"['atxi', 'fbio']",https://twitter.com/fortressbio/status/1339974595391188995,False,,0,,,,,,,,[],,,,
1339588822103834624,1339588820874850310,2020-12-17 20:40:38 IST,2020-12-17,20:40:38,+0530,3213634851,fortressbio,Fortress Biotech,,"Avenue intends to resubmit the New Drug Application (NDA) in February 2021, barring any Covid-19 related or other setbacks. For more information:  https://t.co/Jbbn4blJrF $ATXI $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/322/avenue-therapeutics-provides-regulatory-update-for-iv'],[],0,0,0,[],"['atxi', 'fbio']",https://twitter.com/fortressbio/status/1339588822103834624,False,,0,,,,,,,,[],,,,
1339588820874850310,1339588820874850310,2020-12-17 20:40:37 IST,2020-12-17,20:40:37,+0530,3213634851,fortressbio,Fortress Biotech,,.@AvenueThera provided a regulatory update following receipt of the official meeting minutes from a November 2020 Type A meeting with the U.S. Food and Drug Administration (FDA) relating to a path forward for IV tramadol.  https://t.co/Jbbn4blJrF $ATXI $FBIO,en,"[{'screen_name': 'avenuethera', 'name': 'avenue therapeutics', 'id': '917381549213044737'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/322/avenue-therapeutics-provides-regulatory-update-for-iv'],[],1,0,0,[],"['atxi', 'fbio']",https://twitter.com/fortressbio/status/1339588820874850310,False,,0,,,,,,,,[],,,,
1339542102288556032,1339542102288556032,2020-12-17 17:34:59 IST,2020-12-17,17:34:59,+0530,3213634851,fortressbio,Fortress Biotech,,Avenue Therapeutics Provides Regulatory Update for IV Tramadol  https://t.co/O36x20zOc2 $ATXI $FBIO,ca,[],['https://bit.ly/2LO8Gvb'],[],0,0,0,[],"['atxi', 'fbio']",https://twitter.com/fortressbio/status/1339542102288556032,False,,0,,,,,,,,[],,,,
1339209924488941569,1339209924488941569,2020-12-16 19:35:01 IST,2020-12-16,19:35:01,+0530,3213634851,fortressbio,Fortress Biotech,,"Lung S. Yam, M.D., Ph.D., President and CEO of Cyprium comments on the @US_FDA granting Breakthrough Therapy Designation for CUTX-101 for the treatment of #Menkes disease, and plans for rolling submission of an NDA to begin in Q1 2021  https://t.co/ZJl0ulWR42 $FBIO",en,"[{'screen_name': 'us_fda', 'name': 'u.s. fda', 'id': '208120290'}]",['https://bit.ly/389ukRI'],[],0,0,0,['menkes'],['fbio'],https://twitter.com/fortressbio/status/1339209924488941569,False,,0,,,,,,,,[],,,,
1338848577968349184,1338848574944268292,2020-12-15 19:39:10 IST,2020-12-15,19:39:10,+0530,3213634851,fortressbio,Fortress Biotech,,Rolling submission of #NDA to the @US_FDA for CUTX-101 on track to begin in the first quarter of 2021 and to be completed by the end of the second Quarter of 2021. For more information:  https://t.co/VqofPjwhxG $FBIO,en,"[{'screen_name': 'us_fda', 'name': 'u.s. fda', 'id': '208120290'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/321/fortress-biotech-announces-breakthrough-therapy-designation'],[],0,0,0,['nda'],['fbio'],https://twitter.com/fortressbio/status/1338848577968349184,False,,0,,,,,,,,[],,,,
1338848576965922822,1338848574944268292,2020-12-15 19:39:10 IST,2020-12-15,19:39:10,+0530,3213634851,fortressbio,Fortress Biotech,,"The @US_FDA previously granted Orphan Drug, Fast Track, and Rare Pediatric Disease Designations to CUTX-101 for the treatment of #Menkes disease. Additionally, the @EMA_News previously granted Orphan Drug Designation to CUTX-101.  https://t.co/VqofPjwhxG $FBIO",en,"[{'screen_name': 'us_fda', 'name': 'u.s. fda', 'id': '208120290'}, {'screen_name': 'ema_news', 'name': 'eu medicines agency', 'id': '116716199'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/321/fortress-biotech-announces-breakthrough-therapy-designation'],[],1,0,0,['menkes'],['fbio'],https://twitter.com/fortressbio/status/1338848576965922822,False,,0,,,,,,,,[],,,,
1338848575992762368,1338848574944268292,2020-12-15 19:39:09 IST,2020-12-15,19:39:09,+0530,3213634851,fortressbio,Fortress Biotech,,"Often lethal if untreated, #Menkes disease is an X-linked recessive disorder of copper metabolism caused by mutations in ATP7A, an evolutionarily conserved copper-transporting ATPase.  https://t.co/VqofPjwhxG $FBIO",en,[],['https://www.fortressbiotech.com/news-media/press-releases/detail/321/fortress-biotech-announces-breakthrough-therapy-designation'],[],1,0,0,['menkes'],['fbio'],https://twitter.com/fortressbio/status/1338848575992762368,False,,0,,,,,,,,[],,,,
1338848574944268292,1338848574944268292,2020-12-15 19:39:09 IST,2020-12-15,19:39:09,+0530,3213634851,fortressbio,Fortress Biotech,,"Fortress Biotech announced that the @US_FDA has granted Breakthrough Therapy Designation to Cyprium Therapeutics for CUTX-101, a potential treatment for #Menkes disease.  https://t.co/VqofPjwhxG $FBIO",en,"[{'screen_name': 'us_fda', 'name': 'u.s. fda', 'id': '208120290'}]",['https://www.fortressbiotech.com/news-media/press-releases/detail/321/fortress-biotech-announces-breakthrough-therapy-designation'],[],1,0,0,['menkes'],['fbio'],https://twitter.com/fortressbio/status/1338848574944268292,False,,0,,,,,,,,[],,,,
1338831676848431106,1338831676848431106,2020-12-15 18:32:00 IST,2020-12-15,18:32:00,+0530,3213634851,fortressbio,Fortress Biotech,,"Fortress Biotech Announces Breakthrough Therapy Designation for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease  https://t.co/ZJl0ulWR42 $FBIO",en,[],['https://bit.ly/389ukRI'],[],0,0,0,[],['fbio'],https://twitter.com/fortressbio/status/1338831676848431106,False,,0,,,,,,,,[],,,,
1336675727203311616,1336675727203311616,2020-12-09 19:45:02 IST,2020-12-09,19:45:02,+0530,3213634851,fortressbio,Fortress Biotech,,Reminder: @Mustang_Bio's KOL call on MB-106 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma is today at 1:00 p.m. EST. To register please click  https://t.co/eDmz4nGh6l $MBIO $FBIO,en,"[{'screen_name': 'mustang_bio', 'name': 'mustang bio', 'id': '917400688707166208'}]",['https://lifescipartners.zoom.us/webinar/register/4716055342878/WN_miF0ddQGQ6m9lH7M21aAWQ'],[],0,1,1,[],"['mbio', 'fbio']",https://twitter.com/fortressbio/status/1336675727203311616,False,,0,,,,,,,,[],,,,
1336343542206230530,1336343542206230530,2020-12-08 21:45:03 IST,2020-12-08,21:45:03,+0530,3213634851,fortressbio,Fortress Biotech,,"$FBIO CEO, Lindsay A. Rosenwald, M.D., will participate in the ""COVID And The Effect On BioTech"" panel at the @Benzinga Global Small Cap Conference at 2:45 p.m. EST. Management will present an overview of the company at 3:30 p.m. More info:  https://t.co/hhr8uxhbqd",en,"[{'screen_name': 'benzinga', 'name': 'benzinga', 'id': '44060322'}]",['https://www.benzinga.com/events/small-cap/'],[],0,1,3,[],['fbio'],https://twitter.com/fortressbio/status/1336343542206230530,False,,0,,,,,,,,[],,,,
1336321879859208192,1336321877959065600,2020-12-08 20:18:58 IST,2020-12-08,20:18:58,+0530,3213634851,fortressbio,Fortress Biotech,,"Updated interim results from an open-label, multi-cohort Phase I clinical trial show patients with #mCSCC had robust and durable response rates to cosibelimab. Read more:  https://t.co/4DYRrwrIXN $CKPT $FBIO",en,[],['https://journals.lww.com/oncology-times/Fulltext/2020/12050/Immunotherapy_for_Metastatic_Cutaneous_Squamous.6.aspx'],[],0,0,2,['mcscc'],"['ckpt', 'fbio']",https://twitter.com/fortressbio/status/1336321879859208192,False,,0,,,,,,,,[],,,,
